FIELD: medicine.
SUBSTANCE: to predict the probability of cytoreductive operation at the optimum level in patients with disseminated ovarian cancer, clinical parameters are defined: the disease stage, the amount of ascitic fluid, the level of CA 125 and NE4 serum markers, the level of insulin-like factor II (IGF-II) and PAPP-a metalloproteinase in ascitic fluid prior to treatment. The discriminant functions Y1, Y2 are calculated. For Y1>Y2, a high probability is predicted, and for Y1<Y2, - a low probability of performing a cytoreductive operation in the optimal volume is predicted.
EFFECT: invention allows to determine the stage of surgical and chemotherapeutic treatment in patients with disseminated ovarian cancer.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637410C1 |
| METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
| METHOD FOR DETERMINING THE EFFECTIVENESS OF CHEMOTHERAPY WITH PLATINUM PREPARATIONS IN III-IV STAGE OVARIAN CANCER | 2020 |
|
RU2738167C1 |
| METHOD FOR PREDICTING DURATION OF DISEASE-FREE INTERVAL AFTER COMPLETION OF PRIMARY TREATMENT OF PATIENTS WITH OVARY CANCER | 2018 |
|
RU2676702C2 |
| METHOD FOR PREDICTION OF RISK OF TUMOUR PROGRESSION IN PATIENTS WITH OVARIAN CANCER | 2023 |
|
RU2816339C1 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD OF DETERMINING DURATION OF RECURRENCE-FREE INTERVAL IN SEROUS OVARIAN CANCER | 2015 |
|
RU2613302C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ASCITIC-INFILTRATIVE OVARIAN CANCER AND ABDOMINAL TUBERCULOSIS | 2015 |
|
RU2585959C1 |
| METHOD OF SINGLE-STAGE INSTALLATION OF INTRAPERITONEAL PORT-SYSTEM IN COMBINATION WITH HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC), INCLUDING INTRAOPERATIVE INSTALLATION OF INTRAPERITONEAL PORT-SYSTEM WITH POSSIBILITY OF FURTHER CARRYING OUT OF NORMOTHERMAL CHEMO-PERFUSION THROUGH PORT SYSTEM | 2020 |
|
RU2740628C1 |
